Synonyms: BOS-228 | LYS228
Compound class:
Synthetic organic
|
|
No information available. |
Summary of Clinical Use ![]() |
Ancremonam has progressed to Phase 2 clinical evaluation. Studies in patients with complicated intra-abdominal infections (NCT03354754) and complicated urinary tract infections (NCT03377426) were halted due to a change in sponsor. The new sponsor, Boston Pharmaceuticals has indicated that clinical development will continue. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03377426 | LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) | Phase 2 Interventional | Novartis | ||
NCT03354754 | LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) | Phase 2 Interventional | Novartis |